(TGTX) TG Therapeutics, Inc. Company Overview

What does TG Therapeutics do?

TG Therapeutics, Inc. is a Nasdaq-listed commercial-stage biopharmaceutical company focused on B-cell diseases. Its present economics are unusually concentrated: one medicine, BRIUMVI (ublituximab-xiiy), generates almost all revenue, while a broader clinical program seeks to extend the franchise into new formulations and autoimmune indications. The company describes itself in its 2025 Form 10-K as a fully integrated business spanning acquisition, development and commercialization rather than a royalty-only biotechnology company.

Why is BRIUMVI the center of the company?

BRIUMVI is an anti-CD20 monoclonal antibody approved in the United States for adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. After the starting regimen, the approved intravenous product is administered as a one-hour infusion every 24 weeks. That dosing profile matters commercially because therapy choice in multiple sclerosis reflects efficacy, safety, patient convenience, infusion-center capacity, payer coverage and physician familiarity—not simply molecular novelty.

What sits behind the marketed product?

TG is developing a simplified one-day IV initiation regimen, a self-administered subcutaneous formulation, BRIUMVI in myasthenia gravis and exploratory uses outside multiple sclerosis. It is also testing azer-cel, an allogeneic CD19-directed CAR-T candidate, in progressive multiple sclerosis. This makes the company more than a single-label sales story, but the pipeline remains economically subordinate to current BRIUMVI adoption. For research purposes, the cleanest identity is therefore: a focused B-cell therapeutics company whose value is led by one fast-growing multiple-sclerosis franchise and whose strategic objective is to broaden its addressable market without losing commercial execution.

How does TG Therapeutics make money?

The model begins with BRIUMVI prescriptions and infusions, but reported revenue is shaped by a longer chain: physician adoption, payer authorization, specialty-distributor purchases, gross-to-net deductions and product delivery. U.S. net product sales are the dominant stream. Outside the United States, TG supplies product to Neuraxpharm and can receive royalties, milestones and other collaboration income. The company also owes LFB a high-single-digit royalty on BRIUMVI net sales, so gross margin is strong but not equivalent to software-like economics.

Which revenue stream dominates?

The Q1 2026 mix shows why U.S. prescription momentum overwhelms every other variable in the current income statement. Partner economics are strategically useful because they extend reach without requiring TG to build a full commercial infrastructure country by country, but they are not yet large enough to diversify the earnings base.

How do gross sales become reported sales?

Revenue quality depends on gross-to-net management. At March 31, 2026, TG reported about $27.2 million of related deductions in accounts receivable and $59.0 million in accounts payable and accrued expenses. Those balances reflect rebates and other commercial adjustments that can move with payer mix, channel inventory and utilization. Researchers should therefore avoid equating prescription growth mechanically with revenue growth.

What does TG Therapeutics’ latest quarter show?

The quarter ended March 31, 2026 showed rapid commercial expansion, positive operating income and a much larger balance sheet after new borrowing. TG’s Q1 2026 earnings release raised full-year global revenue guidance to approximately $925 million and U.S. BRIUMVI guidance to $885 million–$900 million. That guidance implies management expects the launch curve to remain strong, but it also raises the execution bar.

Is the quarterly growth durable or merely a launch effect?

Why did profit not translate into positive operating cash flow?

The Q1 2026 Form 10-Q reported operating cash outflow of $17.9 million even though net income was positive. The main working-capital effects included an $86.4 million increase in accounts receivable and a $13.3 million increase in inventory, partly offset by a $34.0 million increase in accounts payable and accrued expenses. That divergence is important: fast revenue growth can consume cash when receivables and inventory expand ahead of collection and utilization.

Which turning points created today’s TG Therapeutics?

TG’s history is best understood as a sequence of portfolio concentration and commercial transition. The company moved from an oncology-oriented development portfolio toward a multiple-sclerosis franchise, then used BRIUMVI’s launch to fund lifecycle management and selected autoimmune expansion. The useful historical question is not what happened first, but which decisions still affect revenue, control over commercialization, royalty burden and clinical risk today.

1. 2011
   Leadership reset. Michael S. Weiss became chief executive, establishing the leadership continuity that still shapes strategy and governance.
2. 2012
   Ublituximab rights acquired. The LFB license created the core asset and the high-single-digit royalty obligation embedded in current product economics.
3. 2020
   ULTIMATE trials succeeded. Positive Phase 3 results transformed ublituximab from a development asset into a credible commercial opportunity in RMS.
4. 2022
   FDA approval. BRIUMVI was approved in December, shifting the company from clinical-stage financing toward launch execution and reimbursement.
5. 2023
   Commercial launch and ex-U.S. partnership. The January U.S. launch created recurring product revenue; the Neuraxpharm agreement extended geographic reach with more than $150 million of upfront and near-term payments within a potential $650 million package.
6. 2024
   Franchise expansion began. TG added azer-cel rights, advanced subcutaneous BRIUMVI work and started returning capital through repurchases.
7. 2026
   Lifecycle programs reached pivotal milestones. ENHANCE met its primary endpoint, the subcutaneous Phase 3 study became fully enrolled, and new autoimmune studies widened the opportunity set.

What did the commercial launch change?

The January 2023 launch changed the company’s strategic constraints. Before launch, capital availability and trial success dominated the analysis. After launch, the relevant questions became prescription conversion, payer access, gross-to-net discipline, supply reliability and commercial productivity. That transition also explains the sharp rise in SG&A, the inventory investment and the growing importance of working capital.

What gives BRIUMVI a competitive position?

BRIUMVI competes in a clinically demanding market where treatment efficacy, safety, convenience, administration setting and payer behavior all matter. Its clearest differentiation is the one-hour maintenance infusion every 24 weeks after the starting dose. TG also points to long-term clinical data and durable B-cell depletion. The company reported six-year data in which 89.9% of patients were free from 24-week confirmed disability progression and the year-six annualized relapse rate was 0.012, although cross-trial comparisons must be treated cautiously.

Which competitors define the market?

Is the moat durable?

TG’s defensibility is therefore a bundle rather than a single moat. It includes intellectual property, regulatory approval, physician experience, payer access, a specialized commercial organization and accumulated safety data. The company says issued patents extend ublituximab protection into 2042, while U.S. biologic reference-product exclusivity runs through December 2034. Those protections matter, but the practical moat will depend on whether the franchise keeps earning share before competitors improve convenience or new mechanisms change standards of care.

How strong are TG Therapeutics’ finances and capital allocation?

TG ended 2025 with $199.5 million of cash, cash equivalents and investment securities, then materially changed its capital structure in Q1 2026. A new $750 million term loan refinanced the prior $250 million facility and increased liquidity. At March 31, 2026, cash and investment securities were $572.8 million, while the loan payable was $745.1 million net of issuance costs. The balance sheet can now fund commercialization, trials and inventory more comfortably, but interest expense and refinancing risk are more important than they were one year earlier.

What does the annual baseline reveal?

FY2025 revenue was $616.3 million, up 87.3% from $329.0 million in FY2024. U.S. BRIUMVI revenue reached $594.1 million, compared with $310.0 million in 2024 and $88.8 million in 2023. Operating income was $123.3 million, an operating margin of approximately 20.0%. Reported net income of $447.2 million was not a clean measure of recurring profitability because it included a $339.8 million income-tax benefit associated largely with releasing a valuation allowance. Operating cash flow was still negative $24.8 million in FY2025.

How is management deploying capital?

The central capital-allocation tension is clear. TG is simultaneously scaling sales, funding pivotal programs, building supply resilience and repurchasing stock while carrying more leverage. None of those choices is automatically inconsistent, but their combination makes cash conversion and return on incremental investment essential metrics.

Who owns TGTX stock, and how is the company governed?

TG has one class of common stock, with one vote per share. The investor base is institutionally influenced rather than controlled through a dual-class structure, yet the chief executive retains meaningful economic exposure and leadership concentration. According to the 2026 proxy statement, 153,093,879 shares were outstanding on the April 14, 2026 record date and the board comprised six directors.

What governance signals deserve attention?

Weiss has served as CEO since December 2011 and also holds the chair and president titles. That continuity can support decisive execution in a focused biotechnology company, but it also concentrates leadership authority. The 2025 advisory say-on-pay proposal received only 54.3% support, a notable signal that compensation design or quantum did not command broad shareholder approval. For an investor, this does not negate operating performance; it means compensation responsiveness and board oversight should be monitored alongside commercial results.

Which pipeline opportunities could change the story?

TG’s highest-quality growth options are those that leverage BRIUMVI’s existing molecule, safety database and commercial infrastructure. Formulation and dosing improvements generally require less strategic reinvention than a new molecular program, although they still face trial, regulatory, manufacturing and adoption risk. Beyond those lifecycle projects, new indications and azer-cel create larger upside ranges with lower evidentiary maturity.

Why is subcutaneous delivery strategically important?

The current IV product competes effectively for patients and physicians who prefer infrequent provider-administered therapy. A quarterly at-home injection could address a different preference set and respond directly to self-administered competition. TG’s June 2026 Phase 1 update reported more than 100 treated patients, including more than 80 who received subcutaneous BRIUMVI, and mean bioavailability above 60% relative to IV administration. The pivotal question is no longer only technical feasibility; it is whether Phase 3 exposure, device bridging, regulatory review and patient adoption all align.

How should early indication expansion be interpreted?

The myasthenia gravis data are encouraging but based on only 11 patients, while the schizophrenia study is open-label and approximately 60 patients. These programs should be modeled as options, not as established revenue streams. Their strategic merit is that they reuse B-cell expertise and potentially the same commercial asset; their risk is that small or uncontrolled studies can overstate efficacy.

What risks could weaken TG Therapeutics’ outlook?

TG’s strongest attribute—focus—also produces its most material vulnerability. One marketed product supports revenue, operating leverage, pipeline funding and the capacity to repurchase stock. A safety issue, reimbursement restriction, manufacturing interruption or competitive loss of share could therefore affect multiple financial lines at once. The company’s risk factors also highlight third-party reliance, uncertain clinical outcomes, regulatory obligations, intellectual-property disputes and the possibility that prescription trends do not persist.

How concentrated is the distribution channel?

Concentration is manageable only when counterparties remain creditworthy and channel ordering tracks real demand. At March 31, 2026, the same four customers represented 38%, 19%, 28% and 13% of accounts receivable. The order differs from gross-revenue ranking, illustrating how payment timing can distort quarter-end balances.

Which KPIs best explain TG Therapeutics’ performance?

A useful TG dashboard must combine commercial, financial and clinical measures. Revenue alone is insufficient because a launch can grow while consuming cash, and a pipeline can generate positive headlines without creating approved economics. The most decision-useful indicators connect demand to revenue quality, revenue to cash and clinical milestones to addressable-market expansion.

How should students connect the KPIs?

The chain is straightforward. New patient starts and treatment persistence drive infusions; infusions and net pricing drive product revenue; gross margin converts revenue into product profit; SG&A and R&D determine operating leverage; working capital determines whether accounting profit becomes cash. Pipeline milestones then affect both future revenue probability and current spending. This framework also captures the substance of a value-chain or VRIO analysis without forcing TG into a generic template.

Why does TG Therapeutics matter for valuation?

A DCF for TG should separate the approved franchise from pipeline options. The approved BRIUMVI business can be modeled with patient adoption, net price, gross-to-net deductions, market duration, operating expense and tax assumptions. The simplified IV and subcutaneous programs deserve probability-adjusted extensions to the franchise, while MG, schizophrenia and azer-cel require lower probabilities and later timing. Blending every program into one aggressive revenue curve would hide the different evidence levels.

Which assumptions create the most sensitivity?

• Peak penetration and duration: small changes compound because BRIUMVI is the dominant revenue source.
• Operating leverage: Q1 2026 showed a 17.0% operating margin, but SG&A and development spending remain large.
• Cash conversion: receivable and inventory growth can delay free cash flow even during GAAP profitability.
• Exclusivity and competition: the model must reflect patent protection, biologic exclusivity and evolving anti-CD20 alternatives.
• Probability-adjusted pipeline value: positive early data should not receive the same weight as an approved indication.
• Capital allocation: repurchases can increase per-share value only when executed below intrinsic value and without weakening needed reinvestment.

What is the key takeaway from TG Therapeutics analysis?

TG Therapeutics has crossed the difficult boundary from development-stage biotechnology to a profitable-on-an-operating-basis specialty-pharma company. BRIUMVI’s U.S. revenue rose from $88.8 million in 2023 to $594.1 million in 2025 and $194.8 million in Q1 2026 alone. That trajectory, an 83.6% quarterly gross margin and positive operating income demonstrate real commercial value. The company also has credible lifecycle opportunities: ENHANCE succeeded, the subcutaneous program is pivotal-stage, and early indication-expansion work creates additional option value.

The counterweight is concentration. One product supports almost the entire model; four distributors represented 98% of Q1 2026 gross product revenue; cash conversion has lagged accounting earnings; and the new term loan materially increased leverage. Competition from established anti-CD20 products remains intense, while early-stage programs cannot yet be treated as dependable revenue. Governance deserves attention as well, particularly leadership concentration and the weak 2025 say-on-pay result.